Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12919971 | 0.78 | AKR1C3 (0.47) | CYP2D6AKR1C3AKR1C2PTGS2BACE1 | |
| SCHEMBL6448616 | 0.76 | DRD2 (0.45) | CYP2D6 | |
| SCHEMBL5549959 | 0.76 | PRKCI (0.45) | CYP2D6ACHEPTGS2CHRM2CHRM1 | |
| SCHEMBL5554008 | 0.74 | SLC6A3 (0.48) | CYP2D6CHRM2CHRM1 | |
| SCHEMBL6447344 | 0.74 | SLC6A3 (0.48) | CYP2D6CHRM2CHRM1 | |
| SCHEMBL6445690 | 0.74 | DPP4 (0.53) | CYP2D6ACHE | |
| SCHEMBL5555136 | 0.74 | DPP4 (0.53) | CYP2D6ACHE | |
| SCHEMBL5550077 | 0.73 | AKR1C3 (0.43) | AKR1C3AKR1C2ACHEPTGS2IDO1 | |
| SCHEMBL5549345 | 0.72 | ACHE (0.49) | ACHE | |
| SCHEMBL5553122 | 0.72 | CYP17A1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | CYP2D6 941/4885AKR1C3 1218/4885AKR1C2 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.